Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 oct. 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014

PORTLAND, Ore., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
14 oct. 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan

- Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2 - Extends...
08 oct. 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(TM) (nelipepimut-S) Combination

PORTLAND, Ore., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
25 sept. 2014 16h15 HE | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Release of Special Committee Report and Hosting of a Conference Call to Provide a Corporate Update

PORTLAND, Ore., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE) today announced the release of a report prepared by the former Special Committee of Galena's Board of Directors...
09 sept. 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

PORTLAND, Ore., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
03 sept. 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

PORTLAND, Ore., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
21 août 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer

PORTLAND, Ore., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
11 août 2014 16h35 HE | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Second Quarter 2014 Results

Abstral® (fentanyl) sublingual tablet net revenue was $2.3 million in Q2 2014 and $4.5 million in 1H 2014. U.S. license of Zuplenz® (ondansetron) oral soluble film expands portfolio...
29 juil. 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014

PORTLAND, Ore., July 29, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
22 juil. 2014 07h05 HE | Source: Galena Biopharma, Inc.

Galena Biopharma Enters Into Definitive Agreement to License U.S. Rights for Zuplenz(R) (ondansetron) Oral Soluble Film

Novel, rapidly dissolving oral PharmFilm® enables faster absorption, increased convenience and better compliance for patients. Planned launch in multiple indications—chemotherapy-,...

Page précédente